The overall objective is to review the ongoing integration of many novel immune therapies and novel targeted therapies into the evolving standards of care, including the use of chemotherapy, for many malignancies. Standards of care are evolving due to a continuing stream of FDA drug approvals, the evolving NCCN and ASCO guidelines and the increasing number of ongoing investigational clinical trials available to patients now.
What makes this activity unique and highly relevant and practical to oncologists, hematologists, nurses, pharmacists, scientists and other cancer HealthCare Professionals (HCPs) is that it concurrently addresses integrating all of these new immune and targeted therapies into routine practice. This is the “real world” situation of how oncologists and hematologists and other HCPs must learn how to optimally incorporate all of these new therapies into their practices.
For a large number of malignancies, e.g., lung cancer, pancreatic cancer, leukemia and melanoma, there are both new and emerging targeted therapies, as well as new and emerging immune therapies. For many patients these new therapies have similar, if not identical indications. Strategies employing these new immune and targeted therapies include single-agent usage, as well as combinations of immune therapy plus targeted therapy, and dual combinations of either class of therapy, and also, the optimal sequencing of these new therapies, especially with the use of established chemotherapy and chemotherapy backbones, for a large number of solid and hematologic malignancies. Treating most malignancies today involves the evaluation of numerous options of different therapies—more than ever before.
Melanoma is a good example malignancy where oncologists are facing dilemmas regarding how to use targeted and immune therapies today: using monotherapy, or dual and sometimes even triple immune or targeted combination therapy. And of course, depending upon the lines of therapy, when to use and switch specific strategies in order to optimize sequencing of therapy is also a critical issue to be understood.
Besides melanoma, a few questions-in-practice and dilemmas for NSCLC, pancreatic cancer and several hematologic malignancies are relevant examples and include: 1) How do clinicians select among the many new, FDA-approved checkpoint inhibitor-based strategies and their many permutations/combinations for improving outcome with NSCLC patients, plus the soon to be FDA-approved additional immune therapies? Similarly, 2) How do clinicians match NSCLC patients with specific EGFR mutations and the three generations of EGFR-directed TKI therapies, plus sequencing all of these 1st 2nd and 3rd generation EGFR-based strategies as monotherapy versus combination therapy for managing EGFR acquired resistance? 3) How do clinicians decide which is the appropriate strategy for 2nd-line non-EGFR mutated NSCLC: Is it a VEGFR-directed targeted therapy strategy or is it an immune-based (checkpoint inhibition) strategy or a taxane monotherapy? or a combination of classes? 4) How do clinicians decide which is better for improving patient outcome: either enrollment in a clinical trial to receive a new immune or targeted strategy, such as an investigational checkpoint inhibitor, or an anti-CDK/4, anti-CDK/6 or other late-stage investigational targeted therapy versus an established taxane chemotherapy approach? 5) How do hematologists begin selecting from the newest immune therapies for several lymphomas versus radiation and stem cell transplants, etc.? 6) How do oncologists integrate the most recent immune and targeted therapy data using novel JAK and BTK inhibition versus CAR T-Cell, stem cells, vaccines and other immune therapies for pancreatic cancer? These dilemmas and critical questions will be addressed in order to optimize the potential benefits from the various and increasing new and emerging therapies that are being integrated into new standards of cancer care.
The increasing use of Next Generation Sequencing (NGS) testing for NSCLC and other malignancies has made the identification of many more biologic targets and pathways as targets that can possibly improve patient outcome. The ability of NGS to identify these new biologic targets such as BRAF, MET, MEK, ROS 1, HER2, etc., for NSCLC, breast cancer and other solid malignancies has expanded the potential list of targeted therapy options for community-based practitioners as well as has increased the options for using the new immune therapies and their combinations with both targeted therapies and in some cases, novel chemotherapies, which are under active clinical investigation. This has expanded the use of NGS testing, used as large gene panels, and also as liquid and even urine based-biopsy ctDNA testing, versus tissue-based testing and FDA-approved companion diagnostic molecular tests.
The standards of cancer care for most malignancies for the forthcoming several years will continue to be evolving with a very large number of options as existing treatment algorithms integrate new immune and new targeted therapies into the traditional systemic anticancer therapies, including chemotherapy and radiation and surgery. This activity will emphasize and facilitate an in-depth understanding of how the new immune and novel targeted therapies are best integrated into standards of care for improving cancer patient outcome.
This activity is designed to meet the educational needs of medical oncologists, hematologists, radiation oncologists, surgical oncologists, pathologists, oncology pharmacists, oncology nurses/Advanced Nurse Practitioners, and other allied healthcare professionals involved in the treatment, care and management of patients with solid and hematologic malignancies that are responsive to immune and targeted therapies. Cancer Is treated optimally by a multi-disciplinary approach of clinicians, and thus, all of the aforementioned clinical specialties are targeted for invitation to this CME/CE activity.
Medical Oncology Faculty
Roy S. Herbst, MD, FRCPC (Co-Chair)
Leo I. Gordon, MD (Co-Chair)
Ranjana H. Advani, MD
Philippe Armand, MD, PhD
Edward Garon, MD
Corey J. Langer, MD
Eileen M. O'Reilly, MD
John M. Pagel, MD, PhD Dsc
Daniel P. Petrylak, MD
Gregory J. Riely, MD, PhD
Stanley R. Riddell, MD
Mario Sznol, MD
Margaret A. Tempero, MD
Heather A. Wakelee, MD
Jeffrey S. Weber, MD, PhD
H. Jack West, MD
Jeffrey Wolf, MD
Oncology Nursing Faculty
Marianne Davies, DNP, ACNP, AOCNP
Oncology Pharmacist Faculty
Jim M. Koeller, MS
BioMedical Learning Institute
LEAD NURSE PLANNER
PLANNER & CME/CE REVIEWER
|CME/CE PEER REVIEWER
Danielle Shafer, MD
I have no real or apparent conflicts of interest to report.
This educational activity has been independently peer-reviewed.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product or consult the Physicians' Desk Reference.
The Biomedical Learning Institute (BMLI) does not recommend the use of any agent outside of the FDA labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the BMLI. Please refer to the official FDA prescribing information for each product for discussion of approved indicated, contraindications, and warnings.
To receive CME/CE credit participation in the entire activity by viewing the activity and the completion of a brief evaluation form, participation in 4 pre- and post-questions, and successfully passing a CME/CE test of 4 questions.
The Biomedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Biomedical Learning Institute designates this enduring activity for a maximum of 8.25 AMA PRA Category 1 Credits™.
Physicians should only claim credit commensurate with the extent of their participation in the activity.
The Biomedical Learning Institute is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credits: 8.25 hours (0.825 ceus)
Type of Activity: Knowledge
The Biomedical Learning Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's COA.
The Biomedical Learning Institute designates this educational activity for 8.25 contact hours.
Accreditation by the American Nurses Credentialing Center's COA refers to recognition of educational activities and does not imply approval or endorsement of any product.
Participation at the entire activity, a 70% or better score on the post-test and completion of the evaluation form is required to receive CE contact hour credit.
Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 8.25 hours of Category 1 credit for attending this symposium.
Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit.
Sincere appreciation is extended to Genentech, Merck, Novartis, Lilly, Celgene, Boehringer Ingelheim, Ariad, Foundation Medicine, Aduro Biotech for their generous support of this educational activity
The educational need for this activity is the result of recent and continuing FDA approvals of new immune therapies and new targeted therapies for a large number of solid and hematologic malignancies. And because for many malignancies these new therapies have similar if not the same indications and usage, it is essential that their new applications within the current standards of care be evaluated concurrently in one symposium. With an understanding of the most current clinical trials’ data and FDA indications involving immune and targeted therapies, it will be possible for HCPs to deliver optimal patient care for many malignancies, resulting in improved outcome.
|Microsoft® Windows Vista®||Microsoft Internet Explorer 7, Firefox 2.0, AOL 9, Microsoft PowerPoint 2003 or later, Adobe Flash Player 8 or later, iTunes 7 or later|
|Microsoft Windows XP||Microsoft Internet Explorer 6.0 or later, Firefox 1.x, Firefox 2.x, Mozilla 1.x or later, Netscape 7.x or later, AOL 9, Opera 7.11 or later, Microsoft PowerPoint 2003 or later, Adobe Flash Player 8 or later, iTunes 7 or later|
|Microsoft Windows Server® 2003||Microsoft Internet Explorer 6.0 or later, Firefox 1.x, Firefox 2.x , Microsoft PowerPoint 2003 or later, Adobe Flash Player 8 or later, iTunes 7 or later|
|Microsoft Windows 2000||Microsoft Internet Explorer 5.x, Firefox 1.x, Firefox 2.x, Mozilla 1.x, Netscape 7.x or later, AOL 9, Opera 7.11 or later, Microsoft PowerPoint 2003 or later, Adobe Flash Player 8 or later, iTunes 7 or later|
|Microsoft Windows Millennium Edition||Microsoft Internet Explorer 5.5, Firefox 1.x, Mozilla 1.x, Netscape 7.x or later, AOL 9, Opera 7.11 or later, Microsoft PowerPoint 2003 or later, Adobe Flash Player 8 or later, iTunes 7 or later|
|Microsoft Windows 98||Microsoft Internet Explorer 6.0 or later, Firefox 1.x, Mozilla 1.x, Netscape 7.x or later, Opera 7.11 or later, Microsoft PowerPoint 2003 or later, Adobe Flash Player 8 or later, iTunes 7 or later|
|Mac OS X v10.1 or later
|Firefox 1.x, Mozilla 1.x, Netscape 7.x or later, AOL for Mac OS X, Opera 6, Safari 1.x or later, Microsoft PowerPoint 2003 or later, Adobe Flash Player 8 or later, iTunes 7 or later|
|Mac OS X v10.4.x or later
|Firefox 184.108.40.206 or later, Opera 6, Safari 2.x or later, Microsoft PowerPoint 2003 or later, Adobe Flash Player 8 or later, iTunes 7 or later|